TNFRSF4 and neoplasm: With access to tumor specimens before and after anti-OX40, we found an increase in CD8+ CD103+ CD39+ cells in the tumor in 4 of 16 patients (3 HPV−, 1 HPV+) after anti-OX40 infusion and none of these patients have had a tumor recurrence.